The category in 2026

Sleep & Growth Hormone is the most established peptide pillar. The molecules — sermorelin, CJC-1295, ipamorelin — have been clinically used for decades, originally for pediatric GH deficiency and increasingly for adult anti-aging, recovery, and sleep-quality applications. The 2026 conversation in this pillar is mature: pulsatile vs sustained GH release, GHRH vs GHRP combinations, the role of exogenous GH (which we don't recommend) versus endogenous secretagogues (which we do cover).

The strategic frame: instead of injecting human growth hormone (suppresses endogenous production, often illegal off-label, expensive), use peptides that prompt the body's own pituitary to release GH in physiologic patterns. The result is GH/IGF-1 elevation that's closer to natural patterns, with a different side-effect and cost profile.

The molecules that matter

Sermorelin — 29-amino-acid GHRH analog. FDA-approved 1997 (as Geref) for pediatric GH deficiency, withdrawn 2008 for commercial reasons, now compounded. Half-life ~10 minutes — produces tight, physiologic GH pulses. Daily SC dosing, typically pre-bed. The most "natural" GH secretagogue option because the pulse pattern mimics endogenous release.

CJC-1295 — Modified GHRH analog. CJC-1295 with DAC has half-life ~8 days; CJC-1295 without DAC ("modified GRF 1-29" or Mod-GRF) has the short physiologic half-life of sermorelin. The DAC version trades pulsatility for convenience (1–2× weekly dosing, sustained GH elevation rather than pulses). The non-DAC version is the more common stack ingredient.

Ipamorelin — Selective ghrelin/GHS-R1a receptor agonist. A GHRP (growth-hormone-releasing peptide) that synergizes with GHRH analogs to amplify GH pulse amplitude. Highly selective — minimal cortisol or prolactin elevation compared to older GHRPs (GHRP-2, GHRP-6, hexarelin). The most commonly stacked GHRP in 2026 protocols.

The standard pairing — CJC-1295 (no DAC) + Ipamorelin — combines GHRH and GHRP mechanisms for amplified pulsatile GH release. Standard dose: 100mcg CJC + 200mcg Ipa subcutaneously 5×/week, 30 minutes pre-bed, in 12-week-on / 4-week-off cycles. Typical IGF-1 response: +60 ng/mL over 12 weeks.

Tesamorelin — 44-amino-acid GHRH analog. FDA-approved (as Egrifta) for HIV-associated visceral fat reduction. Off-label use for visceral adipose tissue reduction in metabolically unhealthy adults — notable as the only FDA-approved member of this category for an adult indication.

The pulsatile-vs-sustained question

The single most-discussed technical question in this pillar is whether sustained GH elevation (CJC-1295 with DAC) or pulsatile GH release (Sermorelin or Mod-GRF + Ipamorelin) is better. The clinical reasoning favors pulsatile: endogenous GH is released in pulses, and tonic (sustained) GH elevation can downregulate receptors and is associated with insulin resistance over time. The convenience reasoning favors sustained: 1–2× weekly DAC injections are easier than 5–7× weekly pulses.

Most 2026 clinical protocols converge on pulsatile (no DAC), with DAC reserved for users who can't commit to daily injections. See the CJC-1295 vs Sermorelin comparison for the head-to-head.

The sleep connection

GH peptides are taken pre-bed not just for convenience but because endogenous GH release peaks during slow-wave sleep. Sermorelin or CJC + Ipa 30 minutes before bed reinforces the natural nocturnal GH pulse. Reported subjective effects: deeper sleep, faster sleep onset, more vivid dreams (associated with REM and slow-wave sleep cycles). The sleep-quality benefit is one of the most consistent reports across protocols, even before any IGF-1 response is measured.

Stacking and cycling

Standard adult GH peptide cycle: CJC-1295 (no DAC) 100 mcg + Ipamorelin 200 mcg subcutaneously 5×/week pre-bed for 12 weeks, then 4 weeks off. The cycling rationale is to prevent receptor downregulation and preserve responsiveness over time. IGF-1 testing pre/post cycle is standard practice; baseline + 12-week measurements are the minimum for evaluating response.

Tesamorelin is dosed differently — 2 mg subcutaneously once daily, not cycled, on indication of metabolic dysfunction (visceral adiposity, fatty liver risk). Tesamorelin can be combined with the Sermorelin/CJC + Ipa stack but more commonly stands alone for its specific indication.

What about exogenous HGH?

Exogenous human growth hormone is FDA-approved only for specific indications (pediatric GH deficiency, AIDS wasting, certain rare conditions). Off-label adult anti-aging use is illegal in the US under the 1990 Anti-Drug Abuse Act and 21 USC 333(e). We don't cover protocols using exogenous HGH; the GH peptide pillar is specifically about endogenous-release alternatives.

The relevant comparison: GH peptides at standard doses produce IGF-1 elevation in the upper half of normal range; exogenous HGH at supraphysiologic doses pushes IGF-1 well above normal range, with proportionally higher side-effect risk and zero added benefit for most users at standard doses.

What we cover under this pillar

All GH peptides: Sermorelin, CJC-1295/Ipamorelin, Tesamorelin
Direct comparisons: CJC-1295 vs Sermorelin
All injectable GH options: /peptides/by-format/injection (filter by Growth hormone)
Find a clinic prescribing GH peptides: /clinics (filter by Growth hormone category)

Open questions we are tracking

Will the July 2026 PCAC ruling include CJC-1295 and Ipamorelin in the bulk substances list?
Does the long-term safety profile of CJC-1295 (with DAC) sustained-elevation pattern hold up at the 5+ year timescale where insulin sensitivity changes accumulate?
What's the optimal cycle length and off-period for sustained GH peptide use? Current 12-on / 4-off is convention rather than evidence-based.
Will tesamorelin's metabolic indication expand beyond HIV-associated lipodystrophy to general visceral adipose tissue?

We update this page as each resolves.

Who should use this pillar

> Evidence tier: 5 — editorial framing of pillar-page audience scope; no clinical evidence claim made.

The Sleep and Growth Hormone pillar serves three primary reader audiences. First, adults in the 35–65 range experiencing age-related decline in sleep quality and recovery capacity — the somatopause demographic, where endogenous GH secretion has dropped 30–50% from young-adult baseline and slow-wave sleep architecture is measurably degraded. Second, patients with documented adult-onset GH insufficiency (post-traumatic, post-surgical, idiopathic) who are evaluating peptide secretagogues against exogenous recombinant GH therapy under endocrinologist supervision. Third, athletes and performance-focused users prioritizing recovery and body composition who are operating outside competition (WADA-prohibited substances are not appropriate for in-competition athletes) and want a more physiologic alternative to exogenous GH.

This pillar is not appropriate for pediatric GH deficiency (a separate FDA-regulated treatment pathway exists), for users with active malignancy (GH-axis stimulation may accelerate certain tumor types), for users with proliferative diabetic retinopathy, or for users with uncontrolled type 2 diabetes (GH antagonizes insulin and can worsen glycemic control). Patients on the Weight Loss pillar stack frequently cross-read this pillar for Tesamorelin as a muscle-sparing adjunct to GLP-1 therapy — that crossover audience gets specific treatment in our compare-page series.

Decision framework — choosing between molecules in this category

> Evidence tier: 5 — editorial decision-framework synthesis from the trial-data benches summarized in the references section.

GH secretagogue selection turns on four questions: pulsatile versus sustained release, daily versus weekly dosing tolerance, IGF-1 elevation target, and route of administration.

Choose Sermorelin when the priority is the most physiologic GH-pulse pattern, when the patient has prior sensitivity to longer-acting analogs, or when the clinician wants the tightest control over IGF-1 elevation. The 10-minute half-life produces the cleanest pulse, but the daily-injection requirement is real.

Choose CJC-1295 without DAC + Ipamorelin when the priority is amplified GH pulse amplitude via the GHRH + GHRP combination mechanism, when the patient can commit to 5×/week subcutaneous dosing, and when IGF-1 elevation targets sit in the upper-normal range. This is the most common 2026 protocol pattern. The CJC-1295 vs Sermorelin comparison covers the differential.

Choose CJC-1295 with DAC when dosing convenience (1–2× weekly) outweighs the receptor-downregulation concern from sustained GH elevation. This is appropriate for short-cycle use (4–8 weeks) but increasingly questioned for multi-year maintenance.

Choose Tesamorelin when the indication is visceral adipose tissue rather than general GH-axis support. This is the only FDA-approved molecule in the category (for HIV-associated lipodystrophy) and the off-label use in metabolically unhealthy adults is supported by reasonable adult-population safety data.

Consider MK-677 (ibutamoren) as a non-peptide oral ghrelin-receptor agonist when injection is a barrier — but be aware of its meaningful side-effect profile (water retention, appetite increase, blood glucose impact) and its WADA-prohibited status.

We do not recommend exogenous recombinant human growth hormone for off-label adult anti-aging use; it is federally illegal in the US under 21 USC 333(e) outside specific FDA-approved indications. The legal and clinical risk profile is meaningfully worse than any peptide secretagogue covered here.

Common questions readers ask

> Evidence tier: 5 — editorial FAQ framing; per-question evidence tiers vary.

Do GH peptides actually improve sleep, or is that just placebo?

The mechanism is real: endogenous GH secretion peaks during stage 3 slow-wave sleep, and exogenous secretagogues administered pre-bed reinforce that natural pulse. Multiple polysomnography studies show GHRH-class peptides increase slow-wave sleep duration and reduce sleep-onset latency. Patient reports of "deeper sleep" and "more vivid dreams" within 1–2 weeks are consistent with the biology. That said, the magnitude of sleep improvement varies widely between users, and any positive effect runs alongside an active placebo effect from the injection ritual itself. Discuss with a clinician if sleep is the primary indication — there are cheaper and better-evidenced sleep interventions to try first.

How long does it take to see results?

IGF-1 elevation is measurable within 2–4 weeks of consistent dosing. Subjective effects on sleep quality often appear within the first week. Body-composition changes (lean mass preservation, modest fat redistribution) typically emerge over 8–16 weeks. Cognitive and recovery effects are reported variably. A reasonable evaluation horizon is one full 12-week cycle with pre/post IGF-1 testing before deciding whether to continue. Setting expectations around the 2–4-month timescale, rather than weekly progress checks, helps users avoid prematurely discontinuing therapy that is on a normal response trajectory.

Is it safe long-term?

The honest answer: long-term (5+ year) safety data on adult GH secretagogue use for non-deficiency indications is limited. The mechanism (endogenous GH/IGF-1 elevation within physiologic ranges) is reasonably distinct from supraphysiologic exogenous GH dosing in safety profile, but the theoretical concerns — insulin resistance over time, theoretical proliferative-disease risk with elevated IGF-1 — are not fully resolved. Annual screening labs (fasting glucose, HbA1c, IGF-1, fasting insulin) plus standard age-appropriate cancer screening are reasonable while on therapy. Discuss with a clinician.

Should I cycle or run it continuously?

Most 2026 protocols use 12-weeks-on, 4-weeks-off cycling to prevent receptor downregulation and preserve GH-pulse responsiveness. Continuous use is sometimes preferred for sustained tesamorelin therapy (HIV-lipodystrophy indication) but is less common for adult anti-aging use. The cycling pattern is convention rather than rigorously evidence-based — no head-to-head trial has tested cycled versus continuous secretagogue use for non-deficiency indications. Discuss with a clinician based on individual response and biomarker trajectory.

Can I take GH peptides alongside GLP-1 weight-loss therapy?

This is the most-asked cross-pillar question, and the answer is generally yes under physician supervision. Tesamorelin is the most commonly stacked GH-axis peptide with GLP-1 therapy (Semaglutide, Tirzepatide) for the "muscle-sparing" indication — preserving lean mass during GLP-1-driven weight loss. The mechanistic rationale is sound: GLP-1 drives weight loss including 25–40% lean-mass loss; GH-axis support promotes lean-mass retention via IGF-1 signaling. The standard pattern is Tesamorelin 2 mg subcutaneous daily alongside titrated GLP-1 therapy with monitoring of fasting glucose, HbA1c, and body composition. Discuss with the prescribing clinician — the combination raises specific glycemic-monitoring considerations.

What we will be tracking

> Evidence tier: 5 — editorial maintenance commitment; no clinical evidence claim made.

The July 23, 2026 PCAC ruling is the single highest-impact event for this pillar — the FDA Pharmacy Compounding Advisory Committee will formally evaluate CJC-1295, Ipamorelin, and Sermorelin for the 503A/503B bulk substances list. The outcome determines whether these peptides remain accessible via legitimate compounding pharmacies or move toward research-only status. We track the situation in the PCAC July 2026 page and will update this pillar within 72 hours of the ruling. On the trial side we are following: any adult somatopause IGF-1-replacement RCT that emerges from the academic-medicine community, Tesamorelin label-expansion efforts beyond HIV-associated lipodystrophy, and long-term safety registry data from the 503A compounding cohort. We are also tracking emerging at-home polysomnography and IGF-1 testing kits that may meaningfully change how patients and clinicians evaluate response to GH peptide therapy. Reader-visible updates will land as each readout or regulatory action lands.

Sleep & Growth Hormone